Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
Arcutis Biotherapeutics(US:ARQT) Globenewswire·2025-11-04 21:00ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved to treat seborrheic dermatitis in adults and adolescents 9 years of age and older WESTLAKE VILLAGE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that the American Journal of Cli ...